Oxford BioTherapeutics (OBT) has entered a multi-year partnership with Roche to discover antibody-based therapeutics for ...

Roche, which put billions on the line a year ago across several ADC pacts, kicked off 2025 by returning to Innovent Biologics ...

Duska noted that the PD-L1 inhibitor pembrolizumab has shown efficacy in the treatment of recurrent or metastatic cervical ...

Luveltamab tazevibulin demonstrated activity in an ongoing phase 2/3 trial of patients with FRα-positive, platinum-resistant ovarian cancer.

Mirvetuximab soravtansine improved overall survival over chemotherapy in patients with FRα-positive, platinum-resistant ovarian cancer.

Adding metformin to letrozole and abemaciclib (Verzenio) was tied to deep responses and prolonged progression-free survival ...

The global polyclonal antibody market is poised for significant expansion in the coming decade, driven by increasing ...

The US Court of Appeals for the Federal Circuit affirmed a district court decision rejecting claims of a patent application directed to a ...

In a precedential opinion issued on March 6, the Federal Circuit affirmed the US District Court for the Eastern District of ...

Apple Inc. v. Gesture Technology Partners, LLC, Appeal Nos. 2023-1475, -1533 (Fed. Cir. Mar. 4, 2025) Our Case of the Week is ...

Background: ImmunoGen’s Patent Application & Dispute. In 2014, ImmunoGen, Inc. (Immunogen) filed U.S. Patent Application No.

In addition to the 3D Epitope Mapping, Proteintech improved the display of its immunogen information. The immunogen data is now displayed as a bar graph at the top of the search return pages, allowing ...